Abstract CT068: A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC)
Davide Melisi
◽
Rocio Garcia-Carbonero
◽
Teresa Macarulla
◽
Denis Pezet
◽
Gaël Deplanque
◽
...